Skip to content
Top Menu
  • Log In
  • Register
  • Facebook
  • Twitter
  • LinkedIn
MyChesCo

MyChesCo

Chester County News and Community Website

  • Communities
    • Avondale
    • Berwyn
    • Coatesville
    • Cochranville
    • Devon
    • Downingtown
    • Exton
    • Honey Brook
    • Kennett Square
    • Malvern
    • Oxford
    • Paoli
    • Parkesburg
    • Phoenixville
    • Spring City
    • Toughkenamon
    • West Chester
    • West Grove
  • Education
    • Chester County Intermediate Unit
    • School Districts
      • Avon Grove School District
      • Coatesville Area School District
      • Downingtown Area School District
      • Great Valley School District
      • Kennett Consolidated School District
      • Octorara Area School District
      • Owen J. Roberts School District
      • Oxford Area School District
      • Phoenixville Area School District
      • Spring-Ford Area School District
      • Tredyffrin-Easttown School District
      • Twin Valley School District
      • Unionville-Chadds Ford School District
      • West Chester Area School District
    • Charter Schools
    • Independent Schools
    • Colleges and Universities
    • Chester County Library System
  • News
    • Traffic
    • Weather
    • Business
    • Health / Medical
    • National
    • Pennsylvania
    • Sports
  • Entertainment
  • Lifestyle
  • Tools
    • Members
    • Groups
    • Submit an Article
    • Contact Us
    • Signup for Newsletter
    • Contests and Giveaways
    • Gas Prices
    • Register
    • Log In
  • About
    • MyChesCo
    • Writing for Us
    • Advertising with Us
    • Contacting Us
    • Citizen Journalism
    • Submitting Articles
    • Starting a Group
    • How to Support Us
    • Terms of Service
    • Privacy Policy
    • DMCA Policy
    • AI Disclosure
  • Shop

Clinical trials

Aprea Therapeutics
Regional

Aprea Therapeutics Reports 2024 Financial Results and Updates on Clinical Innovations

March 26, 2025March 26, 2025 - by Timothy Alexander

DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE), a clinical-stage biopharmaceutical company, shared its financial results for 2024 and provided a progress update on its lead programs aimed at advancing cancer …

Aprea Therapeutics Reports 2024 Financial Results and Updates on Clinical Innovations Read More

iECURE
Regional

iECURE Highlights Promising Results from OTC-HOPE Study at 2025 ACMG Genetics Meeting

March 25, 2025March 24, 2025 - by Timothy Alexander

PHILADELPHIA, PA — iECURE, Inc. recently unveiled encouraging early data from its ongoing OTC-HOPE Phase 1/2 study at the 2025 ACMG Annual Clinical Genetics Meeting. The study, which evaluates the …

iECURE Highlights Promising Results from OTC-HOPE Study at 2025 ACMG Genetics Meeting Read More
Incyte
Regional

Incyte Announces Positive Phase 3 Results for Hidradenitis Suppurativa Treatment

March 23, 2025March 23, 2025 - by Timothy Alexander

WILMINGTON, DE — Biopharmaceutical company Incyte (Nasdaq: INCY) has reported encouraging results from its Phase 3 STOP-HS clinical trials evaluating povorcitinib, an oral JAK1 inhibitor, for moderate to severe hidradenitis suppurativa …

Incyte Announces Positive Phase 3 Results for Hidradenitis Suppurativa Treatment Read More

Annovis Bio
Finance

Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position

March 23, 2025March 22, 2025 - by Timothy Alexander

MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has shared its corporate updates and financial results for the fourth quarter and full year of 2024, highlighting significant advancements in its clinical …

Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position Read More
Johnson & Johnson
Regional

FDA Approves TREMFYA® for Crohn’s Disease, Offering New Treatment Options

March 22, 2025March 21, 2025 - by Timothy Alexander

HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for the treatment of adults with moderately to severely …

FDA Approves TREMFYA® for Crohn’s Disease, Offering New Treatment Options Read More

Traws Pharma
Regional

Traws Pharma Unveils Promising Bird Flu Treatment Data

March 22, 2025March 21, 2025 - by Timothy Alexander

NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) shared encouraging findings on its investigational antiviral drug, tivoxavir marboxil (TXM), during the International Society for Antiviral Research (ICAR 2025) in Las Vegas. …

Traws Pharma Unveils Promising Bird Flu Treatment Data Read More
STRATA Skin Sciences
Regional

Study Validates Advantages of STRATA Skin Sciences’ XTRAC Laser Technology

March 21, 2025March 20, 2025 - by Timothy Alexander

HORSHAM, PA — STRATA Skin Sciences, Inc. (NASDAQ: SSKN) has announced the results of a groundbreaking study conducted in Japan, which underscores the technological advantages of its XTRAC® Excimer Laser over …

Study Validates Advantages of STRATA Skin Sciences’ XTRAC Laser Technology Read More

National Comprehensive Cancer Network
Research

NCCN Launches Free On-Demand Webinar on Cancer Clinical Trials

March 19, 2025March 18, 2025 - by Timothy Alexander

PLYMOUTH MEETING, PA — The National Comprehensive Cancer Network® (NCCN®) has released a free, on-demand webinar titled “Why Should I Consider a Clinical Trial?” to address common questions and misconceptions about …

NCCN Launches Free On-Demand Webinar on Cancer Clinical Trials Read More
Ocugen
Research

Ocugen Advances OCU200 Clinical Trial Amid Promising Safety Results

March 19, 2025March 18, 2025 - by Timothy Alexander

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced progress in its Phase 1 clinical trial for OCU200, a novel biologic designed to treat diabetic macular edema (DME) and related eye conditions. …

Ocugen Advances OCU200 Clinical Trial Amid Promising Safety Results Read More
Mineralys Therapeutics
Regional

Mineralys Therapeutics to Present Phase 2 Advance-HTN Trial Data at ACC.25

March 18, 2025March 18, 2025 - by Timothy Alexander

RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced that its Phase 2 Advance-HTN trial data will be presented during a late-breaking clinical trials session at the American College of …

Mineralys Therapeutics to Present Phase 2 Advance-HTN Trial Data at ACC.25 Read More

Posts pagination

Previous 1 … 7 8 9 … 31 Next

Trending News

  • Education Department Invites States to Cut Red Tape, Pursue Waivers Following Decline in Student Performance

  • HHS Repeals Hospital Incentive for Staff Vaccination Reporting, Citing Need for Medical Autonomy

  • FDA Orders Overhaul of Opioid Labels Amid New Evidence of Long-Term Risks

  • FDA Moves to Restrict Potent Kratom Derivative 7-OH Amid Opioid Abuse Concerns

  • HHS Unveils Ambitious Open Data Plan, Expands HealthData.gov to Boost Transparency and Innovation

Subscribe for Updates

Follow Us

  • Facebook
  • X
  • LinkedIn
  • Google
  • RSS Feed

Tools

  • Members
  • Newsletter
  • Events
  • Groups
  • Guest Articles
  • Coupon Center
  • Gas Prices
  • Log In
  • Register

About Us

  • About MyChesCo
  • Advertise
  • Contact Us
  • Support Us
  • Write for Us
  • Terms of Service
  • Privacy Policy
  • DMCA Policy
  • Affiliate Disclaimer

Recommended Reading

Summer Camp Philadelphia Flyers Visit

Flyers and YMCA Bring Hockey and High-Energy Fun to Coatesville Youth

August 3, 2025August 2, 2025

Arrested

Coatesville Man Accused of Secretly Filming Minors at YMCA Pool; Investigation Ongoing

August 3, 2025August 3, 2025

Crime scene do not cross signage

Wilmington Teen Shot and Critically Injured in Overnight Attack; Police Seeking Tips

August 3, 2025August 2, 2025

Copyright © 2025 MyChesCo.